ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

OPTI Optibiotix Health Plc

15.25
-0.75 (-4.69%)
01 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75 -4.69% 15.25 15.00 15.50 16.25 15.25 16.25 209,970 09:00:24
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 5.37 13.91M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 16p. Over the last year, Optibiotix Health shares have traded in a share price range of 7.35p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £13.91 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 5.37.

Optibiotix Health Share Discussion Threads

Showing 29976 to 29997 of 147875 messages
Chat Pages: Latest  1211  1210  1209  1208  1207  1206  1205  1204  1203  1202  1201  1200  Older
DateSubjectAuthorDiscuss
19/10/2017
09:10
Hi all, I asked Stephen about this and he said:"Our stated aim is to continue to build value in OptiBiotix and this next phase, the commercial phase, is where we see some of the greatest potential for an uplift in value. Whilst we have interest from pharma we would look to work with pharma under license or joint development arrangements to exploit this opportunity. As such we have no plans to sell out to pharma or anyone else before the potential of our technology and products is achieved."
primal123
19/10/2017
08:48
My point is a pharma company is likely to be interested in one division - which would be sold at a premium - and at least the other divisions would remain. Which is much better than the whole company being taken out at an early stage in one go. A 30K buy went through on nex early doors...
parob
19/10/2017
08:36
If pharma interest is as prominent as indicated by recent details here, we would end up in the middle of a bidding war irrespective of being split into divisions. In fact each separate division would be less able to defend its independence.All IMVHO
aspex
19/10/2017
08:32
That's another good reason for splitting and listing each division separately IMO.
parob
19/10/2017
08:07
What worries me is if big pharma are sniffing around we could find ourselves on the end of a bid before our potential is reached. I also dont see any defence against a bid as we have few IIs, thoughts..
zebbo
18/10/2017
23:54
John, don't stress on the side effects unfortunately it's normal... But fortunately it did blow over so to speak :-))
1bokke
18/10/2017
23:37
Funny how life goes.
Before I got (and acted on) this tip in the Penny Share Letter, I'd honestly never heard of the word Microbiome before.
NOW it seems that every day Parob, Primal, Elrico or someone else unearths yet another new article Every day.
It strikes me that this Can't continue without our company making some fantastic headway.
I just can't see how Opti, being positioned as it is, can't take centre stage in all of this narrative, and have some serious re-rating.
I keep wondering, is there something untoward that we're missing, which the Institutional Investors have spotted??
I can't think of anything.

Even my lovely wife is starting to spot articles in the newspapers on the Microbiome!

There might be one downside which we haven't been made aware of. . . .
Since starting this Go Figure regime, I'm seriously concerned at the affect I'm having on the Ozone layer, with all the methane I'm producing !!
Oh dear.

John

2350220
18/10/2017
19:18
Bit more on the antibiotic / microbiome topic

Skinbiotherapeutics Plc: Probiotics to replace antibiotics in wound healing?

Directors Talk article: Did you know that bacteria have antibacterial properties? Its true.


We spoke to Dr Catherine O'neill CEO of Skinbiotix Plc (LON:SBTX) who said, ‘Its worth remembering that penicillin, one of the first antibiotics to be used medically, is derived from a mould. Micro-organisms make antibacterial compounds against each other. Against this background, the hope is that new antibiotics will be discovered in the human microbiome that will help in the fight against antibiotics resistance.’

In a world where antibiotic resistance is becoming a major problem, scientists race in search for alternatives. Could bacteria provide much-needed strategies to prevent life-threatening infections?

The following article provides valuable insight into this and more:

onedayrodders
18/10/2017
18:57
Or a looky chump there Elrico, lol! Very interesting, look forward to hearing of developments in due course, thanks for your opinions!
devonlad
18/10/2017
18:26
Absolutely Elrico."Optibiotix had seen big pharma interest "build" over the past 3-4 months"This suggests conversations have been taking place for a quite a while.
parob
18/10/2017
18:14
Most definitely mate!!!
shrewdmole
18/10/2017
18:02
Does anyone else have a feeling SOH is trying to offer us a clue with todays Proactive interview? SOH usually comments on updates, etc. This seems to have a specific agenda centred around big pharmas interest in LP-LDL.

No I have not asked as this would be futile and make me luck a right chump ;)

elrico
18/10/2017
16:07
Comment from SOH on an unrelated topic I had put to me for SOH related to antibiotics.

"We can’t create new antibiotics but their is growing evidence to suggest that by modifying the microbiome you can increase the effectiveness of a range of therapeutics. In the last few months the level of interest in this area has increased as pharma companies have recognised the potential but also as a result of some high profile failings in drug development."

"We do not intend to enter the pharma market but I have built the company using pharma platforms and covered medical applications in our patent applications so we can partner or license out our technology if the opportunity arises."


Clearly, OPTI have IP ready for pharmaceutical platforms. This is a huge plus for the likes of pharma seeking new drugs and or increase the life of existing drugs because most of the work has been conducted for them. It would save them £ms in R&D and time and most likely a much quicker route to market. What I don't understand at this stage, is how an OTC GRAS scientifically proven products' route to becoming a key ingredient in a pharmaceutical products?

It would be really useful to know the key stages a pharma products route to markets (assuming all is successful) from initial R&D right through to phases 1-3 to final approval from regulatory bodies. Time consuming and expensive for sure!

elrico
18/10/2017
16:00
Semper, Prob both but if Doctor's prescribe surely sales would go through the roof?
deeppockets
18/10/2017
15:19
Deep - would a prescription be needed or just OTC?
semper vigilans
18/10/2017
15:14
Good tip! thanks John :)
smegfish
18/10/2017
15:03
So it looks like SOH is saying they are in serious discussions with big pharma! That's amazing! How about LP-LDL being prescribed by doctors for cholesterol? Bingo!
deeppockets
18/10/2017
14:29
Thanks to everyone who post such interesting articles.
Great to see how the World is waking up to this fantastic story unfolding in front of our eyes.

I would like to offer a very simple tip for anyone posting Web links though:
If you Capitalise the first H in Http it stops ADVFN from changing it to hxxp, and so keeps it as a clickable link.
That saves folk having to copy and past the address, and change the hxxp bit themselves.

John

2350220
18/10/2017
13:24
Yet more microbiome news..

hxxps://www.sciencedaily.com/releases/2017/10/171011123728.htm

smegfish
18/10/2017
13:10
Nice one!
👍

joyjoy13
18/10/2017
12:56
Excellent. Good find primal. So combining with LP-LDL could help extend the patent life of existing drugs. No wonder pharma company interest is increasing.

Looks like Nicktopten's blood pressure reduction is being used as an example! Had a quick look on OPTI's website, but can't see it mentioned - can anyone else?

parob
18/10/2017
12:52
No problem! :) Cannot believe people are selling at this vital period! Each to their own though! As Elrico and Shrewdmole have said we are now reaching that inflection point!
primal123
Chat Pages: Latest  1211  1210  1209  1208  1207  1206  1205  1204  1203  1202  1201  1200  Older

Your Recent History

Delayed Upgrade Clock